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METHODS AND RESULTS:
Baseline blood samples were obtained and patients reported their number of teeth according to the following tooth loss levels: "26-32 (All)" [lowest level], "20-25", "15-19", "1-14", and "No Teeth" [highest level]. Linear and Cox regression models assessed associations between tooth loss levels, biomarker levels and the relationship between tooth loss levels and outcomes, respectively.
After multivariable adjustment, the relative biomarker increase between the highest and the lowest tooth loss level was: high-sensitivity C-reactive protein 1.21 (95% confidence interval, 1.14-1.29), interleukin 6 1.14 (1.10-1.18), lipoprotein-associated phospholipase A 2 activity 1.05 (1.03-1.06), growth differentiation factor 15 1.11 (1.08-1. 14) , and N-terminal pro−B-type natriuretic peptide (NT-proBNP) 1.18 (1.11-1.25) . No association was detected for high-sensitivity troponin T 1.02 (0.98-1.05). Some attenuation of the relationship between tooth loss and outcomes resulted from the addition of biomarkers to the multivariable analysis, of which NT-proBNP had the biggest impact.
CONCLUSIONS:
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INTRODUCTION
There is a growing body of evidence favouring an independent association between oral health and coronary heart disease (CHD) [1] [2] [3] . We have recently reported an association between tooth loss and cardiovascular (CV) outcomes, but not myocardial infarction (MI), in a chronic CHD population [4] . In the literature, the hypothesized relationship between dental disease and CV disease is often attributed to deleterious effects of periodontal disease (PD), a highly prevalent chronic inflammatory condition ranging from early gingivitis to end-stage tooth loss, on the atherosclerotic process but the specific mechanistic nature of such a relationship remains elusive and debated [5] .
Pathophysiological information on multiple aspects of etiology and progression
of CV disease is reflected by several biomarkers, many of which also have robust capabilities of predicting prognosis [6] [7] [8] [9] [10] [11] . Thus, associations between markers of PD, biomarkers and CV outcomes could provide further insights about possible mechanisms connecting PD and CV disease. However, such existing observations mainly stem from smaller populations and are limited to selected inflammatory markers such as C-reactive protein and interleukin-6 [12, 13] , whereas reported associations with other important biomarkers are either scarce or non-existent.
We evaluated associations between self-reported tooth loss, a marker of oral disease and PD, and a wide range of prognostic biomarkers, including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), lipoprotein-associated phospholipase A 2 activity (Lp-PLA 2 ), growth differentiation factor 15 (GDF-15), high-sensitivity troponin T (hs-Troponin T) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in a large global CHD population. Further, we assessed the influence of these biomarkers on the ability of self-reported tooth loss to predict CV outcomes. 
METHODS

Study population
The STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY) study evaluated the efficacy of darapladib, an oral inhibitor of lipoproteinassociated phospholipase A 2 activity (Lp-PLA 2 ) compared to placebo in addition to optimal medical treatment in 15,828 participants from 39 countries with stable CHD, defined as prior myocardial infarction (MI), prior coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), or multivessel CHD without revascularization. At least one additional enrichment criterion was required: age ≥60 years; diabetes mellitus requiring pharmacotherapy; high-density lipoprotein cholesterol <1.03mmol/L; current or previous smoker defined as ≥5 cigarettes per day on average; moderate renal dysfunction (estimated glomerular filtration rate ≥30 and <60mL/min/1.73 m 2 or urine albumin:creatinine ratio ≥30mg albumin/g creatinine); or polyvascular disease (coexisting disease in at least two arterial territories). Patients with an estimated glomerular filtration rate <30mL/min/1.73 m 2 were excluded [14] . After a median follow-up of 3.7 years, no difference in major adverse cardiovascular events (MACE, i.e. first occurrence of CV death, myocardial infarction or stroke) was observed for patients randomized to darapladib compared to placebo [15] . The ethics committees of each participating country approved the study and all patients provided written informed consent prior to inclusion. The STABILITY trial was performed in accordance with the Declaration of Helsinki.
Data collection
At baseline, 15,456 (97%) patients reported their number of teeth according to the following categories: "26-32 (All teeth)", "20-25", "15-19", "1-14", and "No Teeth". For the purposes 8   481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540 of this report, these categories are termed tooth loss levels with 26-32 teeth corresponding to the lowest level and no teeth, the highest level.
Blood samples for routine laboratory tests and storage for later analyses were obtained in all 15,456 patients at baseline and prognostic biomarker analyses were performed in the majority of patients. Plasma aliquots were stored at -70°C until biochemical analysis.
All routine biochemical and hs-CRP analyses were performed at a central laboratory with Analytics e601 was used for the Roche immunoassays.
Statistical analysis
Baseline variables are presented as mean, standard deviation and percentages. Baseline biomarker levels are presented as median and interquartile range. Baseline biomarker levels by tooth loss level were compared using the Kruskal-Wallis tests. 9   541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586 To determine associations between tooth loss levels and biomarker levels, each biomarker was modelled as a function of tooth loss level (five levels). All biomarkers were analyzed on a log-transformed scale using linear models. Geometric mean ratios are presented with 95% confidence intervals (CI) with the lowest tooth loss level (26-32 teeth) as reference, and according to three adjustment models. Model 1 adjusted for randomized treatment. Model 2 adjusted for Model 1 and prior MI, prior coronary revascularization, multi-vessel CHD, age, sex, geographic region, diabetes mellitus, hypertension, renal dysfunction, body mass index, smoking (current, former or never), systolic blood pressure and polyvascular disease. Model 3 adjusted for Model 2 and estimated glomerular filtration rate (according to The Chronic Kidney Disease Epidemiology Collaboration equation, replacing significant renal dysfunction) [16] , hemoglobin, white blood cells, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides. Cox proportional hazards models were used to calculate hazard ratios for MACE, CV death and stroke in relation to tooth loss levels, adjusting for biomarkers in addition to a previously reported multivariable model [4] , co-variables of which are also listed in Table 3 . In these models, all biomarkers except Lp-PLA 2 activity were added after log-transformation. The association between tooth loss and MI has previously been found to be absent in this cohort and was not re-analysed in the present analysis. 589  590  591  592  593  594  595  596  597  598   10   599  600   601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649  650  651 3. RESULTS
Baseline characteristics and associations with biomarkers
Patients with higher tooth loss levels were older, were more likely to be female and had a greater CV risk factor burden, particularly a higher prevalence of smoking, diabetes mellitus, hypertension and impaired renal function compared to those with lower tooth loss levels (Table 1 ). Patients with more tooth loss had progressively higher baseline levels of hs-CRP, IL-6, Lp-PLA 2 activity, GDF-15, hs-Troponin T and NT-proBNP ( Table 2 ). As demonstrated in Figure 1 , higher tooth loss levels were associated with progressively greater relative increases for all prognostic biomarkers in relation to the lowest tooth less level in Model 1.
After multivariable adjustment the association remained statistically significant for all biomarkers, except for hs-Troponin T. Table 3 demonstrates the association between a one-level increase in tooth loss and the risk of MACE, CV death and stroke according to the three adjustment models after a median follow-up of 3.7 years. The data up until Model 2 have been previously presented [4] showing a relative risk increase of 1.06, 1.17 and 1.14 for MACE, CV death and for stroke, respectively, for every one-level increase in tooth loss. The subsequent addition of biomarkers, individually and in groups, only attenuated the results slightly. Nevertheless, the addition of IL-6 and NT-proBNP rendered the association with MACE non-significant.
Tooth loss and outcomes
Despite adjustment for all biomarkers and other co-variables, the association between tooth loss and CV death and stroke persisted. 
DISCUSSION
We found that tooth loss, a marker of PD, was associated with higher levels of several CV biomarkers indicating a potential relationship between tooth loss and several pathophysiological mechanisms relevant to CV morbidity and mortality, including inflammation, cellular integrity and myocardial dysfunction [6, 7, 9, 17] . Adjustment for the biomarkers somewhat attenuated the risk of adverse outcome, signalling a potential relevance of the pathways they represent in the relationship between tooth loss and increased CV risk.
However, much of the risk increase remained, suggesting that other and presently unknown mechanisms could be of importance, although confounding cannot be excluded.
The host-mediated inflammatory response to PD constitutes the most commonly proposed mechanism linking oral disease with CHD and CV disease [18] , mainly based on evidence from smaller studies of moderate associations between various measures of PD and elevation of inflammatory markers [12, 13, 19] and studies showing reductions of CRP and IL-6 levels after PD treatment [20] . This is the first study to corroborate these findings on a large scale in a global CHD population, including both upstream and downstream inflammatory markers, with comprehensive adjustment and with tooth loss as the exposure measure. Moreover, the association with Lp-PLA 2 activity, previously only assessed in small patient populations [21] , could represent an additional alternative and independent inflammatory link [22] . However, our findings could represent a challenge to the inflammation hypothesis as the highest levels of inflammatory markers were observed among the edentulous, who are most likely rid of oral substrates for inflammation. This could indicate that intrinsic factors and not PD explain the inflammatory activity, for instance proinflammatory genetic traits and epigenetic modifications common to both advanced PD and CHD [23, 24] . However, it is also conceivable that many years' exposure to chronic oral inflammation could instigate a secondary response in other locations, e.g. 12   721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780 atherosclerosis in blood vessels, which in turn could promote or maintain an elevated systemic inflammatory response.
Associations with biomarkers that reflect other than inflammatory processes could suggest a relevance of alternative pathophysiological pathways in the tooth loss-CV disease relationship. The association with GDF-15 for instance, has not been previously described and could partly reflect a relationship between tooth loss and inflammation but also other harmful mechanisms [17] of relevance to several cardiac afflictions, including MI and heart failure, to which GDF-15 has been previously associated [25, 26] . An independent association with cardiac biomarkers could support a more specific link between tooth loss, its antecedents, and cardiac pathology. This was previously investigated in a small study where 44 patients with clinical evidence of PD had higher levels of troponin and NT-proBNP compared to controls, however these associations were unadjusted [27] . The association with NT-proBNP in our study suggests a relationship between tooth loss and baseline cardiac dysfunction that persisted after adjustment for traditional important heart failure determinants, including prior MI, hypertension and diabetes. Cross-reactivity between periodontal and myocardial antigens and chronic toll-like receptor activation have been suggested as potential mechanisms linking chronic infection, e.g. PD, to heart failure [28] .
Furthermore, a recent study demonstrated a greater burden of PD among patients with advanced HF awaiting heart transplantation compared to controls without HF. However, the observed differences were attenuated to non-significance after adjustment for markers of oral hygiene, race and 25-hydroxyvitamin D levels [29] . Overall, data on the role of PD in the pathophysiology of heart failure is largely lacking but the results from our present study and other studies are interesting from a hypothesis generating perspective and should be explored further.
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In contrast to the absent MI association we recently reported a significant association between tooth loss and MACE, CV death and stroke. Although the demonstrated risk increases were relatively modest between adjacent tooth loss levels, they were more substantial and likely to be clinically relevant when comparing patients with severe or complete tooth loss to those with little or no tooth loss, particularly for CV death and stroke [4] . In the present analysis, we added biomarkers to the previous outcomes Nevertheless, as our findings are purely observational, causality cannot be inferred and they 14   841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891  892  893  894  895  896  897  898  899  900 may in fact be a product of long-term influence by causal factors common to both tooth loss and CV disease.
From a prediction perspective and irrespective of causality, the observations show promise for the potential use of self-reported tooth loss as a prognostication tool in chronic CHD. Given its ability to predict several important outcomes combined with other qualities, including its straightforward obtainability and affordability, the clinical predictive utility of self-reported tooth loss should be explored further.
Study limitations
Self-reported tooth loss was the sole marker of PD in this analysis and the use of additional exposure measures, e.g. clinical, could have provided better information regarding the underlying etiology of tooth loss in the individual subjects. However, the literature generally exhibits a lack of consistency in the use of PD definitions [5] and PD has been shown to be the most common cause of tooth loss in older populations [31] , although other causes, most importantly caries, must be acknowledged. Moreover, self-reported tooth loss has been validated against number of teeth on clinical examination with concurring results [32] . The cross-sectional multivariable analysis of the association between tooth loss and biomarker levels did not include markers of socioeconomic status, which could be important confounders. Finally, the analysis does not specifically disclose the nature of the observed associations, i.e. whether tooth loss and its underlying mechanisms increases CV risk or vice versa, or if the two conditions are driven by a common etiology.
Conclusion
Self-reported tooth loss was associated with progressively higher levels of several prognostic CV biomarkers suggesting possible involvement of tooth loss-generating mechanisms, 
